


AMENDMENTS TO THE CLAIMS

IN THE CLAIMS:

This listing of claims will replace all prior versions and listings of claims in the application.

Please amend the claims as follows:

1. (Previously presented) A compound of Formula (I):




(I)

wherein

G₁ is (CH₂)_k, where k is 0 to 3;

G₂ is


- a) hydrogen
- b) - C₁₋₆ alkyl;
- c) -aryl;
- d) -C₁₋₆ alkylaryl;
- e)



where R₅ and R₆ are independently selected from the group consisting of


- i) -H;

- ii) -C₁₋₆ alkyl;
- iii) -aryl;
- iv) -C₁₋₆ alkylaryl;
- v) -C(O)-O-C₁₋₆ alkyl;
- vi) -C(O)-O-C₁₋₆ alkylaryl;
- vii) -C(O)-O-C₁₋₆ alkylcycloalkylaryl;
- viii) -C(O)-NH-C₁₋₆ alkyl;
- ix) -C(O)-NH-C₁₋₆ alkylaryl;
- x) -SO₂-C₁₋₆ alkyl;
- xi) -SO₂-C₁₋₆ alkylaryl;
- xii) -SO₂-aryl;
- xiii) -SO₂-NH-C₁₋₆ alkyl;
- xiv) -SO₂-NH-C₁₋₆ alkylaryl;



- xvi) -C(O)-C₁₋₆ alkyl; and
- xvii) -C(O)-C₁₋₆ alkylaryl; or

f) a group of the formula



wherein

R_9 , R_{10} , and R_{11} are independently selected from the group

consisting of

- i) -hydrogen;
- ii) -C₁₋₆ alkyl;
- iii) -aryl;
- iv) -C₁₋₆ alkylaryl;
- v) -C(O)-O-C₁₋₆ alkyl;
- vi) -C(O)-O-C₁₋₆ alkylaryl;
- vii) -C(O)-NH-C₁₋₆ alkyl;
- viii) -C(O)-NH-C₁₋₆ alkylaryl;
- ix) -SO₂-C₁₋₆ alkyl;
- x) -SO₂-C₁₋₆ alkylaryl;
- xi) -SO₂-aryl;
- xii) -SO₂-NH-C₁₋₆ alkyl;
- xiii) -SO₂-NH-C₁₋₆ alkylaryl;
- xiv) -C(O)-C₁₋₆ alkyl; and
- xv) -C(O)-C₁₋₆ alkylaryl; or


R_{10} and R_{11} are taken together to constitute a fused cycloalkyl, fused heterocyclyl, or fused aryl ring containing the atoms to which R_{10} and R_{11} are bonded;

R_1 is


- a) hydrogen;
- b) $-C_{1-6}$ alkyl;
- c) $-aryl$; or
- d) $-C_{1-6}$ alkylaryl;

R_2 is

- a) $-C_{1-6}$ alkyl;
- b) $-aryl$;
- c) $-C_{1-6}$ alkylaryl; or
- d) a group of the formula



wherein m and n are independently selected from 1, 2, 3, or 4; X is a direct bond, CH_2 -, $-O$ -, $-S$ -, $-S(O_2)$ -, $-C(O)$ -, $-CON(H)$ -, $-NHC(O)$ -, $-NHCON(H)$ -, $-NHSO_2$ -, $-SO_2N(H)$ -, $-C(O)-O$ -, $-O-C(O)$ -, $-NHSO_2NH$ -,



-Q₁- is C₁₋₆ alkylene, C₂₋₆ alkenylene, or C₂₋₆ alkynylene;


R₃ is

- a) hydrogen;
- b) -C₁₋₆ alkyl;
- c) -C₁₋₆ alkylaryl; or
- d) -C₁₋₆ alkoxyaryl;

R₄ is

- a)
$$-\text{C}_1-\text{C}_6-\text{alkyl}-\text{C}_6\text{H}_4-\text{L}-\text{C}_1-\text{C}_6-\text{alkyl}-\text{NR}_{14}\text{R}_{15}$$
 ;
- b)
$$-\text{C}_1-\text{C}_6-\text{alkyl}-\text{O}-\text{C}_6\text{H}_4-\text{L}-\text{C}_1-\text{C}_6-\text{alkyl}-\text{NR}_{14}\text{R}_{15}$$
 ; or
- c)
$$\text{C}_6\text{H}_4-\text{L}-\text{C}_1-\text{C}_6-\text{alkyl}-\text{NR}_{14}\text{R}_{15}$$
 ;


wherein L is -CH₂-, -O-, -N(H)-, -S-, SO₂-, -CON(H)-, -NHC(O)-, -NHCON(H)-, -NHSO₂-, -SO₂N(H)-, -C(O)-O-, -NHCO₂NH-, -O-CO-,



R_{36} and R_{37} are independently selected from the group consisting of hydrogen, aryl, $\text{C}_1\text{-C}_6$ alkyl, $\text{C}_1\text{-C}_6$ alkylaryl, $\text{C}_1\text{-C}_6$ alkoxy, and $\text{C}_1\text{-C}_6$ alkoxyaryl

R_{12} and R_{13} are independently selected from the group consisting of hydrogen, $\text{C}_1\text{-C}_6$ alkyl, $\text{C}_1\text{-C}_6$ alkylaryl, and aryl;

R_7 and R_8 are independently selected from the group consisting of hydrogen, $\text{C}_1\text{-C}_6$ alkyl, $\text{C}_1\text{-C}_6$ alkylaryl, and aryl; or R_7 and R_8 are taken together to form a ring having the formula $-(\text{CH}_2)_{o'}-\text{Z}'-(\text{CH}_2)_{p'}-$ bonded to the atoms to which R_7 and R_8 are attached, wherein o' and p' are, independently, 1, 2, 3, or 4; Z' is a direct bond, $-\text{CH}_2-$, $-\text{O}-$, $-\text{S}-$, $-\text{S}(\text{O}_2)-$, $-\text{C}(\text{O})-$, $-\text{CON}(\text{H})-$, $-\text{NHC}(\text{O})-$, $-\text{NHCON}(\text{H})-$, $-\text{NHSO}_2-$, $-\text{SO}_2\text{N}(\text{H})-$, $-\text{C}(\text{O})-\text{O}-$, $-\text{O}-\text{C}(\text{O})-$, $-\text{NHSO}_2\text{NH}-$,




R_{40} and R_{41} are independently selected from the group consisting of hydrogen, aryl, $\text{C}_1\text{-C}_6$ alkyl, and $\text{C}_1\text{-C}_6$ alkylaryl; and

wherein

the aryl and/or alkyl group(s) in R₁, R₂, R₃, R₄, R₅, R₆, R₇, R₈, R₉, R₁₀, R₁₁, R₁₂, and R₁₃ may be optionally substituted 1-4 times with a substituent group, wherein said substituent group(s) or the term substituted refers to groups:

- a) -H;
- b) -Y-C₁₋₆ alkyl;
-Y-aryl;
-Y-C₁₋₆ alkylaryl;
-Y-C₁₋₆-alkyl-NR₁₄R₁₅;
-Y-C₁₋₆-alkyl-W-R₁₆;

wherein Y and W are independently selected from the group consisting of -CH₂-, -O-, -N(H)-, -S-, SO₂-, -CON(H)-, -NHC(O)-, -NHCON(H)-, -NHSO₂-, -SO₂N(H)-, -C(O)-O-, -NHSO₂NH-, -O-CO-,




R₁₆, R₁₇, and R₁₈ are independently selected from the group consisting of hydrogen, aryl, C₁-C₆ alkyl, C₁-C₆ alkylaryl, C₁-C₆ alkoxy, and C₁-C₆ alkoxyaryl; and

- c) halogen, hydroxyl, cyano, carbamoyl, and carboxyl; and


R₁₄ and R₁₅ are independently selected from the group consisting of hydrogen, aryl, C₁-C₆ alkyl, and C₁-C₆ alkylaryl; or

R_{14} and R_{15} are taken together to form a ring having the formula $-(CH_2)_o-Z-(CH_2)_p-$ bonded to the nitrogen atom to which R_{14} and R_{15} are attached, wherein o and p are, independently, 1, 2, 3, or 4; Z is a direct bond, $-CH_2-$, $-O-$, $-S-$, $-S(O_2)-$, $-C(O)-$, $-CON(H)-$, $-NHC(O)-$, $-NHCON(H)-$, $-NHSO_2-$, $-SO_2N(H)-$, $-C(O)-O-$, $-O-C(O)-$, $-NHSO_2NH-$,




R_{19} and R_{20} are independently selected from the group consisting of hydrogen, aryl, C_1 - C_6 alkyl, and C_1 - C_6 alkylaryl.

2. (Previously Presented) The compound of claim 1, represented by Formula (Ia)



wherein G_1 is a direct bond;






R_1 is H;

() is a $-\text{CH}_2-$ group or a direct covalent bond, and x and w are independently equal to 0 to 2, with the proviso that x and w can not both be equal to 0;


R_3 is

- a) hydrogen;
- b) $-\text{C}_{1-6}$ alkyl;
- c) $-\text{C}_{1-6}$ alkylaryl; or
- d) $-\text{C}_{1-6}$ alkoxyaryl;

R_4 is



wherein L is $-\text{CH}_2-$, $-\text{O}-$, $-\text{N}(\text{H})-$, $-\text{S}-$, SO_2- , $-\text{CON}(\text{H})-$, $-\text{NHC}(\text{O})-$, $-\text{NHCON}(\text{H})-$, $-\text{NH}\text{SO}_2-$, $-\text{SO}_2\text{N}(\text{H})-$, $-\text{C}(\text{O})-\text{O}-$, $-\text{NH}\text{SO}_2\text{NH}-$, $-\text{O}-\text{CO}-$, .




R_{36} and R_{37} are independently selected from the group consisting of hydrogen, aryl, $\text{C}_1\text{-C}_6$ alkyl, $\text{C}_1\text{-C}_6$ alkylaryl, $\text{C}_1\text{-C}_6$ alkoxy, and $\text{C}_1\text{-C}_6$ alkoxyaryl

R_6 is

- a) -H ;
- b) -C_{1-6} alkyl;
- c) -aryl ;
- d) -C_{1-6} alkylaryl; or
- e) a group selected from -C(O)R_{25} , -C(O)OR_{25} , $\text{-C(O)NR}_{26}\text{R}_{25}$, $\text{-S(O)}_2\text{R}_{25}$, and $\text{-S(O)}_2\text{NR}_{26}\text{R}_{25}$; wherein R_{25} and R_{26} independently are -C_{1-6} alkyl, aryl, or -C_{1-6} alkylaryl;

R_5 and R_2 are taken together to form a ring of structure



wherein R_{21} , R_{22} , R_{23} and R_{24} independently are


- i) -H ;
- ii) -C_{1-6} alkyl;
- iii) -aryl ;

- iv) -C₁₋₆ alkylaryl; or
 v) a group of the formula -U-R₂₇, wherein U is -C(O)-, -C(O)O-, -O-, -S-, -S(O)-, -S(O)₂-, or -NR₂₈-,
 wherein R₂₇ and R₂₈ independently are -H, -aryl, -C₁₋₆ alkyl, or -C₁₋₆ alkylaryl;

the aryl and/or alkyl group(s) in R₃, R₄, and R₆ may be optionally substituted 1-4 times with a substituent group, wherein said substituent group(s) or the term substituted refers to the groups:

- a) -H;
 b) -Y-C₁₋₆ alkyl;
 -Y-aryl;
 -Y-C₁₋₆ alkylaryl;
 -Y-C₁₋₆-alkyl-NR₁₄R₁₅;
 -Y-C₁₋₆-alkyl-W-R₁₆;

wherein Y and W independently are -CH₂-, -O-, -N(H)-, -S-, SO₂-, -CON(H)-, -NHC(O)-, -NHCON(H)-, -NHSO₂-, -SO₂N(H)-, -C(O)-O-, -NHSO₂NH-, -O-CO-,




R₁₆, R₁₇, and R₁₈ independently are hydrogen, aryl, C₁-C₆ alkyl, C₁-C₆ alkylaryl, C₁-C₆ alkoxy, or C₁-C₆ alkoxyaryl; or

- c) halogen, hydroxyl, cyano, carbamoyl, or carboxyl; and


R₁₄ and R₁₅ independently are hydrogen, aryl, C₁-C₆ alkyl, or C₁-C₆ alkylaryl; or wherein

R₁₄ and R₁₅ may be taken together to form a ring having the formula -(CH₂)_o-Z-(CH₂)_p- bonded to the nitrogen atom to which R₁₄ and R₁₅ are attached, wherein o and p are, independently, 1, 2, 3, or 4; Z is a direct bond, -CH₂-, -O-, -S-, -S(O₂)-, -C(O)-, -CON(H)-, -NHC(O)-, -NHCON(H)-, -NHSO₂-, -SO₂N(H)-, -C(O)-O-, -O-C(O)-, -NHSO₂NH-,




R₁₉ and R₂₀ are hydrogen, aryl, C₁-C₆ alkyl, or C₁-C₆ alkylaryl.

3. (Previously Presented) The compound of claim 1, represented by Formula (Ib)



wherein,
 G₁ is a direct bond;



R₁ is H;

() is a -CH₂- group or a direct covalent bond, and y and z are, independently, an integer of from 0 to 3;

R₃ is

- a) hydrogen;
- b) -C₁₋₆ alkyl;
- c) -C₁₋₆ alkylaryl; or
- d) -C₁₋₆ alkoxyaryl;

R₆ is


- a) -H;
- b) -C₁₋₆ alkyl;
- c) -aryl;
- d) -C₁₋₆ alkylaryl; or
- e) a group selected from -C(O)R₂₅, -C(O)OR₂₅, -C(O)NR₂₆R₂₅, -S(O)₂R₂₅, and -S(O)₂NR₂₆R₂₅; wherein R₂₅ and R₂₆ independently are -C₁₋₆ alkyl, aryl, or -C₁₋₆ alkylaryl;

the aryl and/or alkyl group(s) in R₃, R₄, and R₆ may be optionally substituted 1-4 times with a substituent group, wherein said substituent group(s) or the term substituted refers to groups:

- a) -H;
- b) -Y-C₁₋₆ alkyl;
-Y-aryl;
-Y-C₁₋₆ alkylaryl;
-Y-C₁₋₆-alkyl-NR₁₄R₁₅;

-Y-C₁₋₆-alkyl-W-R₁₆;

wherein Y and W independently are -CH₂-, -O-, -N(H)-, -S-,
 , SO₂-, -CON(H)-, -NHC(O)-, -NHCON(H)-, -NHSO₂-,
 -SO₂N(H)-, -C(O)-O-, -NHSO₂NH-, -O-CO-,




R₁₆, R₁₇, and R₁₈ are hydrogen, aryl, C₁-C₆ alkyl, C₁-C₆ alkylaryl,
 C₁-C₆ alkoxy, or C₁-C₆ alkoxyaryl; or

c) halogen, hydroxyl, cyano, carbamoyl, or carboxyl; and


R₁₄ and R₁₅ independently are hydrogen, aryl, C₁-C₆ alkyl, or C₁-C₆ alkylaryl; and
 wherein

R₁₄ and R₁₅ may be taken together to form a ring having the formula -(CH₂)_o-Z-(CH₂)_p-
 bonded to the nitrogen atom to which R₁₄ and R₁₅ are attached, wherein o and p are,
 independently, 1, 2, 3, or 4; Z is a direct bond, -CH₂-, -O-, -S-, -S(O₂)-, -C(O)-,
 -CON(H)-, -NHC(O)-, -NHCON(H)-, -NHSO₂-, -SO₂N(H)-, -C(O)-O-, -O-C(O)-,
 -NHSO₂NH-,



R₁₉ and R₂₀ are hydrogen, aryl, C₁-C₆ alkyl, or C₁-C₆ alkylaryl;

R₅ and R₂ are taken together to form a ring of structure



wherein R₂₉ and R₃₀ independently are

- a) -H
- b) -C₁₋₆ alkyl;
- c) -aryl;
- d) -C₁₋₆ alkylaryl;
- e) -C(O)-O-C₁₋₆ alkyl;
- f) -C(O)-O-C₁₋₆ alkylaryl;
- g) -C(O)-NH-C₁₋₆ alkyl;
- h) -C(O)-NH-C₁₋₆ alkylaryl;
- i) -SO₂-C₁₋₆ alkyl;
- j) -SO₂-C₁₋₆ alkylaryl;
- k) -SO₂-aryl;
- l) -SO₂-NH-C₁₋₆ alkyl;
- m) -SO₂-NH-C₁₋₆ alkylaryl;
- n) -C(O)-C₁₋₆ alkyl;
- o) -C(O)-C₁₋₆ alkylaryl; or
- p) a group of the formula -V-R₃₁,

wherein V is a group of the formula -C(O), -OC(O)-, -O-, -S-, -S(O)-, -S(O₂)-, -NH-, or -N(R₃₂)-;


wherein R₃₁ and R₃₂ are

- i) -H
- ii) -C₁₋₆ alkyl;
- iii) -aryl;
- iv) -C₁₋₆ alkylaryl;
- v) -C(O)-O-C₁₋₆ alkyl;
- vi) -C(O)-O-C₁₋₆ alkylaryl;
- vii) -C(O)-NH-C₁₋₆ alkyl; -C(O)-NH-C₁₋₆ alkylaryl;
- viii) -SO₂-C₁₋₆ alkyl;
- ix) -SO₂-C₁₋₆ alkylaryl;
- x) -SO₂-aryl;
- xi) -SO₂-NH-C₁₋₆ alkyl;
- xii) -SO₂-NH-C₁₋₆ alkylaryl;
- xiii) -C(O)-C₁₋₆ alkyl; or
- xiv) -C(O)-C₁₋₆ alkylaryl;

wherein R₂₉, R₃₀, R₃₁, and R₃₂ may be optionally substituted 1-4 times with a substituent group, wherein said substituent group(s) or the term substituted refers to groups:

- a) -H;
- b) -L-C₁₋₆ alkyl;
 - L-aryl;
 - L-C₁₋₆ alkylaryl;
 - L-C₁₋₆-alkyl-NR₃₃R₃₄;
 - L-C₁₋₆ alkyl-Q₂-R₃₅;

wherein L and Q₂ independently are -CH₂-, -O-, -N(H)-, -S-,
SO₂-, -CON(H)-, -NHC(O)-, -NHCON(H)-,
NHCO₂-, -SO₂N(H)-, -C(O)-O-, -NHCO₂NH-, -O-CO-,




R_{35} , R_{36} , and R_{37} are hydrogen, aryl, $\text{C}_1\text{-C}_6$ alkyl, $\text{C}_1\text{-C}_6$ alkylaryl, $\text{C}_1\text{-C}_6$ alkoxy, or $\text{C}_1\text{-C}_6$ alkoxyaryl; or

c) halogen, hydroxyl, cyano, carbamoyl, or carboxyl; and


R_{33} and R_{34} independently are hydrogen, aryl, $\text{C}_1\text{-C}_6$ alkyl, or $\text{C}_1\text{-C}_6$ alkylaryl; and wherein

R_{33} and R_{34} may be taken together to form a ring having the formula $-(\text{CH}_2)_e\text{-J-(CH}_2)_k\text{-}$ bonded to the nitrogen atom to which R_{33} and R_{34} are attached, wherein e and k are, independently, 1, 2, 3, or 4; J is a direct bond, $-\text{CH}_2\text{-}$, $-\text{O-}$, $-\text{S-}$, $-\text{S(O}_2\text{)-}$, $-\text{C(O)-}$, $-\text{CON(H)-}$, $-\text{NHC(O)-}$, $-\text{NHCON(H)-}$, $-\text{NHSO}_2\text{-}$, $-\text{SO}_2\text{N(H)-}$, $-\text{C(O)-O-}$, $-\text{O-C(O)-}$, $-\text{NHSO}_2\text{NH-}$,



R_{38} and R_{39} is hydrogen, aryl, $\text{C}_1\text{-C}_6$ alkyl, or $\text{C}_1\text{-C}_6$ alkylaryl.

4. (Previously Presented) The compound of claim 1, represented by Formula (Ic):




wherein,

R₁ is hydrogen, or C₁₋₃ alkylaryl wherein the aryl is substituted with -Y-C₁₋₆ alkylaryl;


R₂ is C₁₋₃ alkylaryl wherein the aryl is substituted with -Y-C₁₋₆ alkylaryl,

wherein Y is -CH₂-, -O-, -N(H)-, -S-, SO₂-, -CON(H)-, -NHC(O)-, -NHCON(H)-, -NHSO₂-, -SO₂N(H)-, -C(O)-O-, -NHSO₂NH-, -O-CO-,



R₁₇, and R₁₈ independently is hydrogen, aryl, C₁-C₆ alkyl, C₁-C₆ alkylaryl, C₁-C₆ alkoxy, or C₁-C₆ alkoxyaryl.

5. (Previously Presented) The compound of claim 1, represented by Formula (Id):




wherein,

R₁ is hydrogen, or C₁₋₃ alkylaryl wherein the aryl is substituted with -Y-C₁₋₆ alkylaryl;

R₂ is C₁₋₃ alkylaryl wherein the aryl is substituted with -Y-C₁₋₆ alkylaryl;

wherein Y is -CH₂-, -O-, -N(H)-, -S-, SO₂-, -CON(H)-, -NHC(O)-, -NHCON(H)-, -NHSO₂-, -SO₂N(H)-, -C(O)-O-, -NHSO₂NH-, -O-CO-,




R₁₇, and R₁₈ independently is hydrogen, aryl, C₁-C₆ alkyl, C₁-C₆ alkylaryl, C₁-C₆ alkoxy, or C₁-C₆ alkoxyaryl;

R₃ is hydrogen or -L-C₁₋₆-alkyl-N(alkyl)₂;


R₁₄ and R₁₅ are alkyl; and

wherein L is -CH₂-, -O-, -N(H)-, -S-, SO₂-, -CON(H)-, -NHC(O)-, -NHCON(H)-, -NHSO₂-, -SO₂N(H)-, -C(O)-O-, -NHSO₂NH-, -O-CO-,



R₃₅, R₃₆, and R₃₇ independently are hydrogen, aryl, C₁-C₆ alkyl, C₁-C₆ alkylaryl, C₁-C₆ alkoxy, or C₁-C₆ alkoxyaryl.


6. (Previously Presented) The compound of claim 1, represented by Formula (Ie):



wherein,

G₁ is a direct bond;

G₂ is a group of the formula



wherein

R₉, R₁₀, and R₁₁ may be hydrogen; or

R₉, R₁₀, and R₁₁ independently are

- i) -C₁₋₆ alkyl;
- ii) -aryl;
- iii) -C₁₋₆ alkylaryl;
- iv) -C(O)-O-C₁₋₆ alkyl;
- v) -C(O)-O-C₁₋₆ alkylaryl;
- vi) -C(O)-NH-C₁₋₆ alkyl;

- vii) $-\text{C}(\text{O})-\text{NH}-\text{C}_{1-6}$ alkylaryl;
- viii) $-\text{SO}_2-\text{C}_{1-6}$ alkyl;
- ix) $-\text{SO}_2-\text{C}_{1-6}$ alkylaryl;
- x) $-\text{SO}_2$ -aryl;
- xi) $-\text{SO}_2-\text{NH}-\text{C}_{1-6}$ alkyl;
- xii) $-\text{SO}_2-\text{NH}-\text{C}_{1-6}$ alkylaryl;
- xiii) $-\text{C}(\text{O})-\text{C}_{1-6}$ alkyl; or
- xiv) $-\text{C}(\text{O})-\text{C}_{1-6}$ alkylaryl; or

R_{10} and R_{11} may be taken together to constitute a fused cycloalkyl, fused heterocyclyl, or fused aryl ring containing the atoms to which R_{10} and R_{11} are bonded;

R_1 is H;

R_2 is

- a) $-\text{C}_{1-6}$ alkyl;
- b) -aryl; or
- c) $-\text{C}_{1-6}$ alkylaryl;


R_3 is

- a) hydrogen;
- b) $-\text{C}_{1-6}$ alkyl;
- c) $-\text{C}_{1-6}$ alkylaryl; or
- d) $-\text{C}_{1-6}$ alkoxyaryl;

the aryl and/or alkyl group(s) in R_2 , R_3 , R_4 , R_9 , R_{10} , R_{11} may be optionally substituted 1-4 times with a substituent group, wherein said substituent group(s) or the term substituted refers to groups:

- a) -H;
- b) -Y-C₁₋₆ alkyl;
 -Y-aryl;
 -Y-C₁₋₆ alkylaryl;
 -Y-C₁₋₆-alkyl-NR₁₄R₁₅;
 -Y-C₁₋₆-alkyl-W-R₁₆;

wherein Y and W independently are -CH₂-, -O-, -N(H)-, -S-,
 SO₂-, -CON(H)-, -NHC(O)-, -NHCON(H)-,
 -NHSO₂-, -SO₂N(H)-, -C(O)-O-, -NHSO₂NH-, -O-CO-,




R₁₆, R₁₇, and R₁₈ are hydrogen, aryl, C₁-C₆ alkyl, C₁-C₆ alkylaryl,
 C₁-C₆ alkoxy, or C₁-C₆ alkoxyaryl; or

- c) halogen, hydroxyl, cyano, carbamoyl, or carboxyl; and


R₁₄ and R₁₅ independently are hydrogen, aryl, C₁-C₆ alkyl, or C₁-C₆ alkylaryl; and
 wherein

R₁₄ and R₁₅ may be taken together to form a ring having the formula -(CH₂)_o-Z-(CH₂)_p-
 bonded to the nitrogen atom to which R₁₄ and R₁₅ are attached, wherein o and p are,
 independently, 1, 2, 3, or 4; Z is a direct bond, -CH₂-, -O-, -S-, -S(O₂)-, -C(O)-,
 -CON(H)-, -NHC(O)-, -NHCON(H)-, -NHSO₂-, -SO₂N(H)-, -C(O)-O-, -O-C(O)-,
 -NHSO₂NH-,




R_{19} and R_{20} independently are hydrogen, aryl, $\text{C}_1\text{-C}_6$ alkyl, or $\text{C}_1\text{-C}_6$ alkylaryl;

7. (Previously Presented) The compound of claim 1, represented by Formula (If):




wherein,
 G_1 is a direct bond;




R_1 is H;

R_2 is a group of the formula



wherein m and n are independently selected from 1, 2, 3, or 4; X is a direct bond, -CH₂-, -O-, -S-, -S(O₂)-, -C(O)-, -CON(H)-, -NHC(O)-, -NHCON(H)-, -NHSO₂-, -SO₂N(H)-, -C(O)-O-, -O-C(O)-, -NHSO₂NH-,



-Q₁- is C₁₋₆ alkylene, C₂₋₆ alkenylene, or C₂₋₆ alkynylene;

R₁₂ and R₁₃ independently is hydrogen, C₁-C₆ alkyl, C₁-C₆ alkylaryl, or aryl;
 and wherein

R₃ is

- a) hydrogen;
- b) -C₁₋₆ alkyl;
- c) -C₁₋₆ alkylaryl; or
- d) -C₁₋₆ alkoxyaryl;

R₅ and R₆ independently are


- a) -H;
- b) -C₁₋₆ alkyl;
- c) -aryl;
- d) -C₁₋₆ alkylaryl; or

- e) a group selected from $-C(O)R_{25}$, $-C(O)OR_{25}$, $-C(O)NR_{26}R_{25}$, $-S(O)_2R_{25}$, and $-S(O)_2NR_{26}R_{25}$; wherein R_{25} and R_{26} independently are $-C_{1-6}$ alkyl, aryl, and $-C_{1-6}$ alkylaryl;

the aryl and/or alkyl group(s) in R_3 , R_4 , R_5 , R_6 , R_{12} , and R_{13} may be optionally substituted 1-4 times with a substituent group, wherein said substituent group(s) or the term substituted refers to groups:

- a) $-H$;
- b) $-Y-C_{1-6}$ alkyl;
 $-Y$ -aryl;
 $-Y-C_{1-6}$ alkylaryl;
 $-Y-C_{1-6}$ -alkyl- $NR_{14}R_{15}$;
 $-Y-C_{1-6}$ -alkyl- $W-R_{16}$;

wherein Y and W independently are $-CH_2-$, $-O-$, $-N(H)-$, $-S-$, SO_2- , $-CON(H)-$, $-NHC(O)-$, $-NHCON(H)-$, $-NHSO_2-$, $-SO_2N(H)-$, $-C(O)-O-$, $-NHSO_2NH-$, $-O-CO-$,




R_{16} , R_{17} , and R_{18} independently are hydrogen, aryl, C_1-C_6 alkyl, C_1-C_6 alkylaryl, C_1-C_6 alkoxy, or C_1-C_6 alkoxyaryl; or

- c) halogen, hydroxyl, cyano, carbamoyl, or carboxyl; and

R_{14} and R_{15} independently is hydrogen, aryl, C_1-C_6 alkyl, or C_1-C_6 alkylaryl; and wherein

R₁₄ and R₁₅ may be taken together to form a ring having the formula $-(CH_2)_o-Z-(CH_2)_p-$ bonded to the nitrogen atom to which R₁₄ and R₁₅ are attached, wherein o and p are, independently, 1, 2, 3, or 4; Z is a direct bond, $-CH_2-$, $-O-$, $-S-$, $-S(O_2)-$, $-C(O)-$, $-CON(H)-$, $-NHC(O)-$, $-NHCON(H)-$, $-NHSO_2-$, $-SO_2N(H)-$, $-C(O)-O-$, $-O-C(O)-$, $-NHSO_2NH-$,



R₁₉ and R₂₀ independently are hydrogen, aryl, C₁-C₆ alkyl, or C₁-C₆ alkylaryl.

8. Canceled.

9. Canceled.

10. Canceled.

11. (Previously Presented) The compound of claim 1, wherein the compound is 3-(4-Benzyloxyphenyl)propionic Acid 2,4-Di-(3-Diethylamino-1-propoxy)aniline Amide.

12. (Previously Presented) The compound of claim 61, wherein the compound is 3-(3-Tert-butoxyphenyl)-3-(9-fluorenylmethoxycarbonylamino)propionic Acid 2,4-Di-(3-diethylaminopropoxy)aniline Amide.

13. (Previously Presented) The compound of claim 62, wherein the compound is 3-(3-Tert-butoxyphenyl)-3-aminopropionic Acid 2,4-Di-(3-diethylaminopropoxy)aniline Amide.

14. (Previously Presented) The compound of claim 1, wherein the compound is 3-(4-Tetrahydropyranyl)-2-aminopropionic Acid 4-Diethylaminoethoxycarbonyl-2-butoxyaniline Amide Dihydrochloride.

15. (Previously Presented) The compound of claim 1, wherein the compound is (2S, 4R)-4-Tert-Butoxypyrrolidine-2-carboxylic acid 2,4-Di(3-diethylamino-1-propoxy)aniline Amide.

16. (Previously Presented) The compound of claim 1, wherein the compound is (3S)-1,2,3,4-Tetrahydroisoquinoline-3-carboxylic Acid 4-Diethylaminoethoxycarbonyl-2-butoxyaniline Amide Dihydrochloride.

17. (Previously Presented) The compound of claim 1, wherein the compound is (R)-3-(4-Benzyloxyphenyl)-2-(1-imidazolyl)propionic Acid 4-Diethylaminoethoxycarbonyl-2-butoxyaniline Amide.

18. (Previously Presented) The compound of claim 61, wherein the compound is 3-(4-Tert-butoxyphenyl)-3-(9-fluorenylmethoxycarbonylamino)propionic Acid 2,4-Di-(3-diethylaminopropoxy)aniline Amide.

19. (Previously Presented) The compound of claim 62, wherein the compound is 3-amino-3-(4-tert-butoxyphenyl)propionic Acid 2,4-Di-(3-diethylaminopropoxy)aniline Amide.

20. (Previously Presented) The compound of claim 61, wherein the compound is 3-(9-fluorenylmethoxycarbonylamino)-3-(2-tert-butoxyphenyl)propionic Acid 2,4-Di-(3-diethylaminopropoxy)aniline Amide.

21. (Previously Presented) The compound of claim 62, wherein the compound is 3-amino-3-(2-tert-butoxyphenyl)propionic Acid 2,4-Di-(3-diethylaminopropoxy)aniline Amide.

22. (Previously Presented) The compound of claim 62, wherein the compound is 3-Isopropylamino-3-(3-tert-butoxyphenyl)propionic Acid 2,4-Di-(3-diethylaminopropoxy)aniline Amide.

23. (Previously Presented) The compound of claim 1, wherein the compound is (2R)-2-tert-butoxycarbonylamino-3-[4-(benzyloxy)phenyl]propionic Acid 4-(3-diethylaminopropoxy)-N- benzylaniline Amide.

24. (Previously Presented) The compound of claim 1, wherein the compound is (2R)-2-tert-butoxycarbonylamino-3-[4-(benzyloxy)phenyl]propionic Acid 4-(3-diethylaminopropoxy)-N- cyclopentylmethylaniline Amide.

25. (Previously Presented) The compound of claim 1, wherein the compound is (2R)-2-tert-butoxycarbonylamino-3-[4-(benzyloxy)phenyl]propionic Acid 4-(3-diethylaminopropoxy)-N- isopropylaniline Amide.

26. (Previously Presented) The compound of claim 1, wherein the compound is (2R)-2-amino-3-[4-(benzyloxy)phenyl]propionic Acid 4-(3-diethylaminopropoxy)-N- cyclohexylmethylaniline Amide.

27. (Previously Presented) The compound of claim 1, wherein the compound is (2R)-2-amino-3-[4-(benzyloxy)phenyl]propionic Acid 4-(3-diethylaminopropoxy)-N-cyclopentylmethylaniline Amide.

28. (Previously Presented) The compound of claim 1, wherein the compound is (2R)-2-tert-butoxycarbonylamino-3-[4-(benzyloxy)phenyl]propionic Acid 4-(3-diethylaminopropoxy)-N-butylaniline Amide.

29. (Previously Presented) The compound of claim 1, wherein the compound is (2R)-2-amino-3-[4-(benzyloxy)phenyl]propionic Acid 4-(3-diethylaminopropoxy)-N-butylaniline Amide.

30. (Previously Presented) The compound of claim 1, wherein the compound is (2R)-2-tert-butoxycarbonylamino-3-[4-(benzyloxy)phenyl]propionic Acid 3-(3-diethylaminopropoxy)-N-butylaniline Amide.

31. (Previously Presented) The compound of claim 1, wherein the compound is (2R)-2-amino-3-[4-(benzyloxy)phenyl]propionic Acid 3-(3-diethylaminopropoxy)-N-butylaniline Amide.

32. (Previously Presented) The compound of claim 1, wherein the compound is 3-(1-Tert-butoxycarbonylpiperidin-4-yl)-2-(9-fluorenylmethoxycarbonylamino)propionic Acid 4-Diethylaminopropoxy-2-butoxyaniline Amide.

33. (Previously Presented) The compound of claim 1, wherein the compound is 3-(Piperidin-4-yl)-2-(9-fluorenylmethoxycarbonylamino)propionic Acid 4-Diethylaminopropoxy-2-butoxyaniline Amide.

34. (Previously Presented) The compound of claim 1, wherein the compound is 3-(1-Benzylpiperidin-4-yl)-2-(9-fluorenylmethoxycarbonylamino)propionic Acid 4-Diethylaminopropoxy-2-butoxyaniline Amide.

35. (Previously Presented) The compound of claim 1, wherein the compound is 3-(1-Benzylpiperidin-4-yl)-2-aminopropionic Acid 4-Diethylaminopropoxy-2-butoxyaniline Amide.

36. (Previously Presented) The compound of claim 1, wherein the compound is 3-(1-Benzylloxycarbonylpiperidin-4-yl)-2-(9-fluorenylmethoxycarbonylamino)propionic Acid 4-Diethylaminopropoxy-2-butoxyaniline Amide.

37. (Previously Presented) The compound of claim 1, wherein the compound is 3-(1-Benzoylpiperidin-4-yl)-2-(9-fluorenylmethoxycarbonylamino)propionic Acid 4-Diethylaminopropoxy-2-butoxyaniline Amide.

38. (Previously Presented) The compound of claim 1, wherein the compound is 3-(1-Benzoylpiperidin-4-yl)-2-benzoylaminopropionic Acid 4-Diethylaminopropoxy-2-butoxyaniline Amide.

39. (Previously Presented) The compound of claim 1, wherein the compound is 3-(Tert-butoxycarbonylpiperidin-3-yl)-2-(9-fluorenylmethoxycarbonylamino)propionic Acid 4-Diethylaminopropoxy-2-butoxyaniline Amide.

40. (Previously Presented) The compound of claim 1, wherein the compound is 3-(Piperidin-3-yl)-2-(9-fluorenylmethoxycarbonylamino)propionic Acid 4-Diethylaminopropoxy-2-butoxyaniline Amide.

41. (Original) A pharmaceutical composition comprising the compound of Formula (I) as claimed in claim 1, and one or more pharmaceutically acceptable carriers, excipients, or diluents.

42. (Original) The pharmaceutical composition of claim 41, in the form of an oral dosage or parenteral dosage unit.

43. (Original) The pharmaceutical composition of claim 41, wherein said compound is administered as a dose in a range from about 0.01 to 500 mg/kg of body weight per day.

44. (Original) The pharmaceutical composition of claim 41, wherein said compound is administered as a dose in a range from about 0.1 to 200 mg/kg of body weight per day.

45. (Original) The pharmaceutical composition of claim 41, wherein said compound is administered as a dose in a range from about 0.1 to 100 mg/kg of body weight per day.

46. (Original) The pharmaceutical composition of claim 41, further comprising one or more therapeutic agents selected from the group consisting of alkylating agents, antimetabolites, plant alkaloids, antibiotics, hormones, biologic response modifiers, analgesics, NSAIDs, DMARDs, glucocorticoids, sulfonylureas, biguanides, insulin, cholinesterase inhibitors, antipsychotics, antidepressants, and anticonvulsants.

47. (Original) A method for the inhibition of the interaction of RAGE with its physiological ligands, which comprises administering to a subject in need thereof, at least one compound of Formula (I) as claimed in claim 1.

48. (Original) The method of claim 47, wherein the ligand(s) is(are) selected from advanced glycated end products (AGEs), S100/calgranulin/EN-RAGE, β -amyloid and amphoterin.

49. (Original) A method for treating a disease state selected from the group consisting of acute and chronic inflammation, symptoms of diabetes, vascular permeability, nephropathy, atherosclerosis, retinopathy, Alzheimer's disease, erectile dysfunction, and tumor invasion and/or metastasis, which comprises administering to a subject in need thereof a therapeutically effective amount of at least one compound of Formula (I) as claimed in claim 1.

50. (Original) A method of prevention and/or treatment of RAGE mediated human diseases comprising administration to a human in need thereof a therapeutically effective amount of a compound of Formula (I) as claimed in claim 1, wherein a therapeutically effective amount comprises sufficient compound to at least partially inhibit the binding of a ligand to the RAGE receptor.

51. (Original) The method of claim 50, further comprising administering to a subject in need thereof at least one adjuvant and/or additional therapeutic agent(s).

52. (Original) A method of claim 51, wherein therapeutic agents selected from the group consisting of alkylating agents, antimetabolites, plant alkaloids, antibiotics, hormones, biologic response modifiers, analgesics, NSAIDs, DMARDs, glucocorticoids, sulfonyleureas, biguanides, insulin, cholinesterase inhibitors, antipsychotics, antidepressants, and anticonvulsants.

53. (Previously Presented) The method of claim 50, wherein the RAGE mediated human disease comprises acute and/or chronic inflammation.

54. (Currently Amended) The method of claim 50, wherein the RAGE mediated human disease comprises ~~comprising~~ vascular permeability.

55. (Currently Amended) The method of claim 50, wherein the RAGE mediated human disease comprises ~~comprising~~ nephropathy ~~ephropathy~~.

56. (Previously Presented) The method of claim 50, wherein the RAGE mediated human disease comprises atherosclerosis.

57. (Currently Amended) The method of claim 50, wherein the RAGE mediated human disease comprises ~~comprising~~ retinopathy.

58. (Currently Amended) The method of claim 50, wherein the RAGE mediated human disease comprises ~~comprising~~ Alzheimer's disease.


59. (Previously Presented) The method of claim 50, wherein the RAGE mediated human disease comprises erectile dysfunction.

60. (Previously Presented) The method of claim 50, wherein the RAGE mediated human disease comprises tumor invasion and/or metastasis.

61. (Previously presented) The compound of claim 1, wherein

G₁ is -CH₂-


G₂ is



wherein

R₅ and R₆ are independently selected from the group consisting of

- i) -H;
- ii) -C₁₋₆ alkyl;
- iii) -aryl;
- iv) -C₁₋₆ alkylaryl;
- v) -C(O)-O-C₁₋₆ alkyl;
- vi) -C(O)-O-C₁₋₆ alkylaryl;
- vii) -C(O)-O-C₁₋₆ alkylcycloalkylaryl;
- viii) -C(O)-NH-C₁₋₆ alkyl;
- ix) -C(O)-NH-C₁₋₆ alkylaryl;
- x) -SO₂-C₁₋₆ alkyl;
- xi) -SO₂-C₁₋₆ alkylaryl;
- xii) -SO₂-aryl;
- xiii) -SO₂-NH-C₁₋₆ alkyl;
- xiv) -SO₂-NH-C₁₋₆ alkylaryl;




- xvi) -C(O)-C₁₋₆ alkyl; or
- xvii) -C(O)-C₁₋₆ alkylaryl;

R₁ is


- a) hydrogen;
- b) -C₁₋₆ alkyl;
- c) -aryl; or
- d) -C₁₋₆ alkylaryl;

R₂ is

- a) $-C_{1-6}$ alkyl;
- b) $-aryl$;
- c) $-C_{1-6}$ alkylaryl; or
- d) a group of the formula



wherein m and n are independently selected from 1, 2, 3, or 4; X is a direct bond, CH_2 -, $-O$ -, $-S$ -, $-S(O_2)$ -, $-C(O)$ -, $-CON(H)$ -, $-NHC(O)$ -, $-NHCON(H)$ -, $-NHSO_2$ -, $-SO_2N(H)$ -, $-C(O)-O$ -, $-O-C(O)$ -, $-NHSO_2NH$ -,




$-Q_1-$ is C_{1-6} alkylene, C_{2-6} alkenylene, or C_{2-6} alkynylene;


R_3 is

- a) hydrogen;
- b) $-C_{1-6}$ alkyl;
- c) $-C_{1-6}$ alkylaryl; or
- d) $-C_{1-6}$ alkoxyaryl;; and

R_4 is



wherein L is -CH₂-, -O-, -N(H)-, -S-, SO₂-, -CON(H)-, -NHC(O)-, -NHCON(H)-, -NHSO₂-, -SO₂N(H)-, -C(O)-O-, -NHSO₂NH-, -O-CO-,




R₃₆ and R₃₇ are independently selected from the group consisting of hydrogen, aryl, C₁-C₆ alkyl, C₁-C₆ alkylaryl, C₁-C₆ alkoxy, and C₁-C₆ alkoxyaryl;

R₁₂ and R₁₃ are independently selected from the group consisting of hydrogen, C₁-C₆ alkyl, C₁-C₆ alkylaryl, and aryl;

R₇ and R₈ are independently selected from the group consisting of hydrogen, C₁-C₆ alkyl, C₁-C₆ alkylaryl, and aryl; or R₇ and R₈ are taken together to form a ring having the formula -(CH₂)_{o'}-Z'-(CH₂)_{p'}- bonded to the atoms to which R₇ and R₈ are attached, wherein o' and p' are, independently, 1, 2, 3, or 4; Z' is a direct bond, -CH₂-, -O-, -S-, -

S(O₂)-, -C(O)-, -CON(H)-, -NHC(O)-, -NHCON(H)-, -NHSO₂-, -SO₂N(H)-, -C(O)-O-, -O-C(O)-, -NHSO₂NH-,




R₄₀ and R₄₁ are independently selected from the group consisting of hydrogen, aryl, C₁-C₆ alkyl, and C₁-C₆ alkylaryl; and

wherein

the aryl and/or alkyl group(s) in R₁, R₂, R₃, R₄, R₅, R₆, R₇, R₈, R₁₂ and R₁₃ may be optionally substituted 1-4 times with a substituent group, wherein said substituent group(s) or the term substituted refers to groups:

- a) -H;
- b) -Y-C₁₋₆ alkyl;
 -Y-aryl;
 -Y-C₁₋₆ alkylaryl;
 -Y-C₁₋₆-alkyl-NR₁₄R₁₅;
 -Y-C₁₋₆-alkyl-W-R₁₆;

wherein Y and W are independently selected from the group consisting of -CH₂-, -O-, -N(H)-, -S-, SO₂-, -CON(H)-, -NHC(O)-, -NHCON(H)-, -NHSO₂-, -SO₂N(H)-, -C(O)-O-, -NHSO₂NH-, -O-CO-,




R₁₆, R₁₇, and R₁₈ are independently selected from the group consisting of hydrogen, aryl, C₁-C₆ alkyl, C₁-C₆ alkylaryl, C₁-C₆ alkoxy, and C₁-C₆ alkoxyaryl; and

c) halogen, hydroxyl, cyano, carbamoyl, and carboxyl; and

R₁₄ and R₁₅ are independently selected from the group consisting of hydrogen, aryl, C₁-C₆ alkyl, and C₁-C₆ alkylaryl; or

R₁₄ and R₁₅ are taken together to form a ring having the formula -(CH₂)_o-Z-(CH₂)_p- bonded to the nitrogen atom to which R₁₄ and R₁₅ are attached, wherein o and p are, independently, 1, 2, 3, or 4; Z is a direct bond, -CH₂-, -O-, -S-, -S(O₂)-, -C(O)-, -CON(H)-, -NHC(O)-, -NHCON(H)-, -NHSO₂-, -SO₂N(H)-, -C(O)-O-, -O-C(O)-, -NHSO₂NH-,




R₁₉ and R₂₀ are independently selected from the group consisting of hydrogen, aryl, C₁-C₆ alkyl, and C₁-C₆ alkylaryl.

62. (Previously Presented) The compound of claim 61,

wherein

G₁ is -CH₂-

G₂ is



wherein


R₅ is -H; and

R₆ is

- i) -H;
- ii) -C₁₋₆ alkyl; or
- iii) -C(O)-O-C₁₋₆ alkylcycloalkylaryl;



R₁ is -H;


R₂ is




R₃ is -H; and

R₄ is





wherein L is -CH₂-, -O-, -N(H)-, -S-, SO₂-, -CON(H)-, -NHC(O)-, -NHCON(H)-, -NHSO₂-, -SO₂N(H)-, -C(O)-O-, -NHSO₂NH-, -O-CO-,



R₃₆ and R₃₇ are independently selected from the group consisting of hydrogen, aryl, C₁-C₆ alkyl, C₁-C₆ alkylaryl, C₁-C₆ alkoxy, and C₁-C₆ alkoxyaryl;


and wherein

the aryl and/or alkyl group(s) in R₁, R₂, R₃, R₄, R₅, R₆, R₇, R₈, R₁₂ and R₁₃ may be optionally substituted 1-4 times with a substituent group, wherein said substituent group(s) or the term substituted refers to groups:

- a) -H;
- b) -Y-C₁₋₆ alkyl;
 -Y-aryl;
 -Y-C₁₋₆ alkylaryl;
 -Y-C₁₋₆-alkyl-NR₁₄R₁₅;
 -Y-C₁₋₆-alkyl-W-R₁₆;

wherein Y and W are independently selected from the group consisting of -CH₂-, -O-, -N(H), -S-, SO₂-, -

CON(H)-, -NHC(O)-, -NHCON(H)-, -NHSO₂-, -SO₂N(H)-,
 -C(O)-O-, -NHSO₂NH-, -O-CO-,




R₁₆, R₁₇, and R₁₈ are independently selected from the group consisting of hydrogen, aryl, C₁-C₆ alkyl, C₁-C₆ alkylaryl, C₁-C₆ alkoxy, and C₁-C₆ alkoxyaryl; and

c) halogen, hydroxyl, cyano, carbamoyl, or carboxyl; and

R₁₄ and R₁₅ are independently selected from the group consisting of hydrogen, aryl, C₁-C₆ alkyl, and C₁-C₆ alkylaryl; or

R₁₄ and R₁₅ are taken together to form a ring having the formula -(CH₂)_o-Z-(CH₂)_p- bonded to the nitrogen atom to which R₁₄ and R₁₅ are attached, wherein o and p are, independently, 1, 2, 3, or 4; Z is a direct bond, -CH₂-, -O-, -S-, -S(O₂)-, -C(O)-, -CON(H)-, -NHC(O)-, -NHCON(H)-, -NHSO₂-, -SO₂N(H)-, -C(O)-O-, -O-C(O)-, -NHSO₂NH-,



R₁₉ and R₂₀ are independently selected from the group consisting of hydrogen, aryl, C₁-C₆ alkyl, and C₁-C₆ alkylaryl.